Tyrese Haliburton Stats, Game Log, News, Profile & Fantasy

Previous game (@ Celtics 5/23)

PTS

REB

AST

BLK

STL

Latest Tyrese Haliburton news

Haliburton (hamstring) won't play in Game 4 of the Eastern Conference Finals against Boston on Monday, Joe Vardon of The Athletic reports. Haliburton appeared to be trending in the wrong direction leading up to tipoff, and he's since been downgraded to out. T.J. McConnell filled in admirably in Game 3, so he figures to be leaned on heavily Monday along with Ben Sheppard and Andrew Nembhard.

2023-24 Postseason Stats

PTS

REB

AST

BLK

STL

18.7

4.8

8.2

0.7

1.3

2.1

2023-24 Season Stats

PTS

REB

AST

BLK

STL

20.1

3.9

10.9

0.7

1.2

2.3

Career Averages

PTS

REB

AST

BLK

STL

17.2

3.7

8.7

0.6

1.5

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	TD3	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2023-24	69	68	32.2	20.1	3.9	10.9	0.7	1.2	2.3	44	1	2.8	7.8	36.4%	4.4	7.4	59.5%	7.2	15.2	47.7%	2.8	3.3	85.5%	0.5	3.4	1.1	4.7	+294	60.5%
2022-23	56	56	33.6	20.7	3.7	10.4	0.4	1.6	2.5	32	0	2.9	7.2	40.0%	4.5	7.8	57.2%	7.4	15.0	49.0%	3.1	3.6	87.1%	0.6	3.1	1.2	4.1	-35	62.4%
2021-22	77	77	35.0	15.3	4.0	8.2	0.6	1.7	2.6	25	0	2.1	5.1	41.4%	3.5	6.8	51.7%	5.6	11.8	47.3%	2.1	2.5	84.2%	0.8	3.2	1.6	3.2	-327	59.5%
2020-21	58	20	30.1	13.0	3.0	5.3	0.5	1.3	1.6	5	0	2.1	5.1	40.9%	2.9	5.6	52.9%	5.0	10.7	47.2%	0.8	1.0	85.7%	0.7	2.3	1.4	3.4	-180	58.5%
Career	260	221	32.9	17.2	3.7	8.7	0.6	1.5	2.3	106	1	2.5	6.2	39.3%	3.8	6.9	55.5%	6.3	13.1	47.8%	2.2	2.6	85.6%	0.6	3.0	1.3	3.8	-248	60.4%

Career Averages

PTS

REB

AST

BLK

STL

18.7

4.8

8.2

0.7

1.3

Year	GP	GS	MIN	PTS	REB	AST	BLK	STL	TO	DD2	TD3	3PM	3PA	3P%	2PM	2PA	2P%	FGM	FGA	FG%	FTM	FTA	FT%	OREB	DREB	PF	A/TO	+/-	TS%
2023-24	15	15	34.8	18.7	4.8	8.2	0.7	1.3	2.1	4	1	3.5	9.3	37.9%	3.5	5.0	69.3%	7.0	14.3	48.8%	1.1	1.3	85.0%	0.8	4.0	0.9	4.0	+59	62.6%
Career	15	15	34.8	18.7	4.8	8.2	0.7	1.3	2.1	4	1	3.5	9.3	37.9%	3.5	5.0	69.3%	7.0	14.3	48.8%	1.1	1.3	85.0%	0.8	4.0	0.9	4.0	+59	62.6%

Regular Season
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
4/14	ATL	W 157-115	25	12	2	13	1	3	2	4	0	0.0%	6	5	83.3%	10	5	50.0%	3	2	66.7%	0	2	6.5	+27	3	21	53.0%
4/12	CLE	L 129-120	35	19	6	12	0	1	5	10	4	40.0%	3	3	100.0%	13	7	53.8%	1	1	100.0%	0	6	2.4	-11	1	26	70.7%
4/9	TOR	W 140-123	31	30	5	5	1	2	2	8	3	37.5%	8	7	87.5%	16	10	62.5%	10	7	70.0%	0	5	2.5	+15	1	34	73.5%
4/7	MIA	W 117-115	32	12	4	8	2	0	3	7	2	28.6%	3	1	33.3%	10	3	30.0%	4	4	100.0%	0	4	2.7	+3	2	17	51.0%
4/5	OKC	W 126-112	35	8	2	11	0	1	2	6	2	33.3%	2	1	50.0%	8	3	37.5%	0	0	0.0%	0	2	5.5	+0	1	14	50.0%
4/3	BKN	L 115-111	36	24	3	8	2	2	0	14	5	35.7%	8	4	50.0%	22	9	40.9%	1	1	100.0%	1	2	0.0	+3	0	25	53.5%
4/1	BKN	W 133-111	26	27	4	13	1	1	0	7	4	57.1%	8	5	62.5%	15	9	60.0%	5	5	100.0%	0	4	0.0	+26	1	41	78.5%
3/29	LAL	W 109-90	33	21	8	8	0	2	2	8	3	37.5%	7	4	57.1%	15	7	46.7%	4	4	100.0%	0	8	4.0	+27	2	30	62.6%
3/27	CHI	L 125-99	31	13	4	5	0	0	2	11	3	27.3%	4	1	25.0%	15	4	26.7%	3	2	66.7%	2	2	2.5	-7	2	7	39.8%
3/25	LAC	W 133-116	31	21	1	9	0	2	3	9	6	66.7%	3	1	33.3%	12	7	58.3%	1	1	100.0%	0	1	3.0	+3	2	26	84.4%
3/24	LAL	L 150-145	32	12	6	10	0	2	1	6	2	33.3%	7	3	42.9%	13	5	38.5%	0	0	0.0%	1	5	10.0	-12	1	18	46.2%
3/22	GSW	W 123-111	37	26	2	11	3	4	1	8	4	50.0%	10	5	50.0%	18	9	50.0%	5	4	80.0%	0	2	11.0	+25	0	38	64.4%
3/20	DET	W 122-103	25	20	3	9	0	4	2	3	1	33.3%	10	8	80.0%	13	9	69.2%	2	1	50.0%	0	3	4.5	+18	1	30	72.0%
3/18	CLE	L 108-103	32	14	6	12	1	1	3	9	1	11.1%	5	3	60.0%	14	4	28.6%	5	5	100.0%	1	5	4.0	-7	5	21	43.2%
3/16	BKN	W 121-100	30	14	7	4	1	2	2	9	1	11.1%	9	5	55.6%	18	6	33.3%	1	1	100.0%	0	7	2.0	+19	0	14	38.0%
3/13	CHI	L 132-129	38	17	3	14	1	0	2	6	1	16.7%	7	5	71.4%	13	6	46.2%	4	4	100.0%	0	3	7.0	-22	3	26	57.6%
3/12	OKC	W 121-111	35	18	4	12	2	2	4	6	2	33.3%	9	6	66.7%	15	8	53.3%	0	0	0.0%	0	4	3.0	+7	0	27	60.0%
3/10	ORL	W 111-97	35	20	7	8	0	0	4	6	1	16.7%	9	5	55.6%	15	6	40.0%	7	7	100.0%	0	7	2.0	+14	2	22	55.3%
3/7	MIN	L 113-111	37	23	3	13	0	1	5	7	2	28.6%	8	7	87.5%	15	9	60.0%	4	3	75.0%	0	3	2.6	-1	1	32	68.6%
3/5	DAL	W 137-120	31	19	6	11	1	0	2	10	3	30.0%	5	5	100.0%	15	8	53.3%	0	0	0.0%	1	5	5.5	+18	2	26	63.3%
3/3	SAS	L 117-105	36	12	6	8	1	0	1	6	0	0.0%	10	4	40.0%	16	4	25.0%	4	4	100.0%	3	3	8.0	-14	0	14	33.8%
3/1	NOP	L 129-102	22	0	3	3	0	0	1	6	0	0.0%	1	0	0.0%	7	0	0.0%	0	0	0.0%	0	3	3.0	-40	0	3	0.0%
2/28	NOP	W 123-114	33	17	3	13	1	1	1	8	3	37.5%	7	4	57.1%	15	7	46.7%	0	0	0.0%	0	3	13.0	+11	0	25	56.7%
2/26	TOR	L 130-122	32	9	0	7	0	2	1	6	1	16.7%	5	1	20.0%	11	2	18.2%	6	4	66.7%	0	0	7.0	-16	0	7	33.0%
2/25	DAL	W 133-111	31	17	3	10	0	4	1	5	1	20.0%	10	7	70.0%	15	8	53.3%	0	0	0.0%	0	3	10.0	+13	0	26	56.7%
2/22	DET	W 129-115	33	25	2	13	0	2	5	10	4	40.0%	8	6	75.0%	18	10	55.6%	1	1	100.0%	0	2	2.6	+12	0	31	67.8%
2/14	TOR	W 127-125	34	21	4	12	0	2	1	9	5	55.6%	4	1	25.0%	13	6	46.2%	5	4	80.0%	0	4	12.0	+2	3	27	69.1%
2/12	CHA	L 111-102	34	13	6	12	0	0	3	8	3	37.5%	7	2	28.6%	15	5	33.3%	0	0	0.0%	1	5	4.0	+10	1	16	43.3%
2/10	NYK	W 125-111	30	22	3	12	1	0	1	9	4	44.4%	5	3	60.0%	14	7	50.0%	5	4	80.0%	0	3	12.0	+11	0	32	67.9%
2/8	GSW	L 131-109	25	5	1	11	1	1	3	4	1	25.0%	3	1	33.3%	7	2	28.6%	0	0	0.0%	0	1	3.7	-9	1	10	35.7%
2/6	HOU	W 132-129	29	18	2	7	2	1	2	6	2	33.3%	9	6	66.7%	15	8	53.3%	1	0	0.0%	0	2	3.5	-1	1	19	58.3%
2/4	CHA	W 115-99	20	17	1	4	2	1	1	5	3	60.0%	3	3	100.0%	8	6	75.0%	3	2	66.7%	0	1	4.0	+13	0	23	91.2%
2/2	SAC	L 133-122	21	14	3	1	0	1	5	3	1	33.3%	7	5	71.4%	10	6	60.0%	1	1	100.0%	1	2	0.2	-15	1	10	67.0%
2/1	NYK	L 109-105	21	15	4	5	2	0	1	6	2	33.3%	4	4	100.0%	10	6	60.0%	1	1	100.0%	0	4	5.0	+5	1	20	71.8%
1/30	BOS	L 129-124	22	13	3	10	0	1	1	5	1	20.0%	11	4	36.4%	16	5	31.3%	2	2	100.0%	3	0	10.0	-4	1	16	38.5%
1/19	POR	L 118-115	34	21	2	17	0	0	0	7	2	28.6%	7	4	57.1%	14	6	42.9%	9	7	77.8%	0	2	0.0	+16	1	34	58.5%
1/8	BOS	W 133-131	13	7	2	6	0	0	2	3	1	33.3%	2	2	100.0%	5	3	60.0%	0	0	0.0%	0	2	3.0	-4	1	10	70.0%
1/6	BOS	L 118-101	34	17	6	7	0	5	4	9	2	22.2%	8	3	37.5%	17	5	29.4%	5	5	100.0%	1	5	1.8	-14	1	19	44.3%
1/5	ATL	W 150-116	25	10	8	18	1	2	2	4	2	50.0%	2	2	100.0%	6	4	66.7%	0	0	0.0%	1	7	9.0	+24	1	34	83.3%
1/3	MIL	W 142-130	33	31	2	12	3	1	0	11	5	45.5%	9	5	55.6%	20	10	50.0%	6	6	100.0%	0	2	0.0	+21	1	41	68.5%
1/1	MIL	W 122-113	36	26	9	11	1	1	2	7	1	14.3%	15	10	66.7%	22	11	50.0%	3	3	100.0%	1	8	5.5	-5	0	37	55.7%
12/30	NYK	W 140-126	35	22	5	23	1	2	2	10	2	20.0%	7	6	85.7%	17	8	47.1%	4	4	100.0%	1	4	11.5	+19	0	44	58.6%
12/28	CHI	W 120-104	37	21	3	20	1	2	0	13	6	46.2%	4	1	25.0%	17	7	41.2%	2	1	50.0%	0	3	0.0	+32	2	35	58.7%
12/26	HOU	W 123-117	37	33	6	10	0	1	3	13	7	53.8%	8	6	75.0%	21	13	61.9%	1	0	0.0%	1	5	3.3	+15	0	37	77.0%
12/23	ORL	L 117-110	39	29	2	15	0	3	3	5	3	60.0%	17	9	52.9%	22	12	54.5%	3	2	66.7%	0	2	5.0	+8	2	35	62.2%
12/21	MEM	L 116-103	37	17	4	14	0	0	4	12	2	16.7%	7	5	71.4%	19	7	36.8%	2	1	50.0%	0	4	3.5	+1	2	17	42.8%
12/20	CHA	W 144-113	27	19	3	13	1	1	4	9	3	33.3%	5	3	60.0%	14	6	42.9%	4	4	100.0%	1	2	3.3	+32	0	28	60.3%
12/18	LAC	L 151-127	30	8	2	11	0	0	4	5	1	20.0%	7	2	28.6%	12	3	25.0%	2	1	50.0%	0	2	2.8	-37	1	7	31.1%
12/15	WAS	L 137-123	27	19	2	11	0	0	4	6	2	33.3%	11	5	45.5%	17	7	41.2%	3	3	100.0%	1	1	2.8	-18	2	16	51.9%
12/13	MIL	L 140-126	30	22	5	7	0	0	3	4	1	25.0%	12	7	58.3%	16	8	50.0%	7	5	71.4%	1	4	2.3	-14	0	24	57.7%
12/11	DET	W 131-123	32	14	5	16	2	1	7	6	3	50.0%	6	2	33.3%	12	5	41.7%	1	1	100.0%	0	5	2.3	+8	2	24	56.3%
12/7	MIL	W 128-119	36	27	7	15	1	0	0	9	3	33.3%	10	8	80.0%	19	11	57.9%	2	2	100.0%	3	4	0.0	+0	1	41	67.9%
12/4	BOS	W 122-112	40	26	10	13	0	1	0	11	5	45.5%	7	5	71.4%	18	10	55.6%	1	1	100.0%	3	7	0.0	+15	2	40	70.5%
11/30	MIA	L 142-132	39	44	2	10	1	3	2	16	6	37.5%	12	9	75.0%	28	15	53.6%	12	8	66.7%	0	2	5.0	-6	0	50	66.1%
11/27	POR	L 114-110	35	33	2	9	0	0	3	6	3	50.0%	11	8	72.7%	17	11	64.7%	9	8	88.9%	0	2	3.0	-3	1	38	78.7%
11/24	DET	W 136-113	32	26	2	10	0	0	1	13	5	38.5%	10	4	40.0%	23	9	39.1%	3	3	100.0%	0	2	10.0	+9	0	24	53.5%
11/22	TOR	L 132-131	34	33	3	16	1	0	3	10	5	50.0%	12	7	58.3%	22	12	54.5%	5	4	80.0%	1	2	5.3	+4	3	39	68.2%
11/21	ATL	W 157-152	38	37	5	16	1	3	6	15	9	60.0%	3	2	66.7%	18	11	61.1%	7	6	85.7%	1	4	2.7	+16	0	53	87.8%
11/19	ORL	L 128-116	25	12	2	3	1	0	4	3	1	33.3%	11	3	27.3%	14	4	28.6%	3	3	100.0%	0	2	0.8	-30	2	1	39.2%
11/14	PHI	W 132-126	38	33	7	15	1	2	0	12	7	58.3%	6	4	66.7%	18	11	61.1%	5	4	80.0%	1	6	0.0	+19	1	52	81.7%
11/12	PHI	L 137-126	36	25	1	17	1	2	0	6	3	50.0%	8	6	75.0%	14	9	64.3%	4	4	100.0%	0	1	0.0	+4	0	42	79.3%
11/9	MIL	W 126-124	38	29	6	10	1	0	2	9	5	55.6%	8	5	62.5%	17	10	58.8%	4	4	100.0%	1	5	5.0	+14	1	40	77.3%
11/8	UTA	W 134-118	30	16	6	13	0	1	2	6	1	16.7%	6	5	83.3%	12	6	50.0%	3	3	100.0%	1	5	6.5	-1	0	31	60.1%
11/6	SAS	W 152-111	27	23	2	8	1	1	2	7	3	42.9%	12	6	50.0%	19	9	47.4%	2	2	100.0%	0	2	4.0	+27	1	22	57.8%
11/4	CHA	L 125-124	36	43	2	12	1	0	3	12	8	66.7%	9	6	66.7%	21	14	66.7%	7	7	100.0%	0	2	4.0	+8	2	52	89.3%
11/3	CLE	W 121-116	34	18	2	13	0	2	4	5	0	0.0%	9	5	55.6%	14	5	35.7%	9	8	88.9%	0	2	3.3	+3	2	19	50.1%
10/30	CHI	L 112-105	36	19	5	13	0	2	4	8	1	12.5%	8	5	62.5%	16	6	37.5%	7	6	85.7%	1	4	3.3	+2	1	27	49.8%
10/28	CLE	W 125-113	32	21	8	13	0	0	1	7	4	57.1%	9	3	33.3%	16	7	43.8%	3	3	100.0%	1	7	13.0	-1	2	30	60.6%
10/25	WAS	W 143-120	26	20	3	11	2	1	3	6	2	33.3%	10	7	70.0%	16	9	56.3%	0	0	0.0%	0	3	3.7	+6	1	25	62.5%
Regular Season Totals			32.2	20.1	3.9	10.9	0.7	1.2	2.3	7.8	2.8	36.4%	7.4	4.4	59.5%	15.2	7.2	47.7%	3.3	2.8	85.5%	0.5	3.4	4.7	+293	1.1	28.5	60.5%

Postseason
Date	Opp	Result	MIN	PTS	REB	AST	BLK	STL	TO	3PA	3PM	3P%	2PA	2PM	2P%	FGA	FGM	FG%	FTA	FTM	FT%	OREB	DREB	A/TO	+/-	PF	PER	TS%
5/23	BOS	L 126-110	27	10	4	8	0	1	0	6	2	33.3%	2	2	100.0%	8	4	50.0%	0	0	0.0%	0	4	0.0	+1	0	19	62.5%
5/21	BOS	L 133-128	40	25	3	10	1	3	3	14	6	42.9%	4	2	50.0%	18	8	44.4%	3	3	100.0%	0	3	3.3	-11	2	31	64.7%
5/19	NYK	W 130-109	32	26	4	6	1	1	2	12	6	50.0%	5	4	80.0%	17	10	58.8%	1	0	0.0%	1	3	3.0	+21	2	27	74.5%
5/17	NYK	W 116-103	32	15	6	9	2	0	1	8	3	37.5%	4	3	75.0%	12	6	50.0%	0	0	0.0%	0	6	9.0	+11	0	25	62.5%
5/14	NYK	L 121-91	33	13	2	5	2	2	2	4	1	25.0%	5	4	80.0%	9	5	55.6%	2	2	100.0%	0	2	2.5	-22	0	20	65.8%
5/12	NYK	W 121-89	27	20	6	5	0	0	0	10	4	40.0%	5	4	80.0%	15	8	53.3%	0	0	0.0%	0	6	0.0	+31	2	21	66.7%
5/10	NYK	W 111-106	38	35	4	7	1	2	2	16	6	37.5%	10	8	80.0%	26	14	53.8%	1	1	100.0%	0	4	3.5	+16	1	36	66.2%
5/8	NYK	L 130-121	34	34	6	9	0	3	2	11	7	63.6%	8	4	50.0%	19	11	57.9%	6	5	83.3%	2	4	4.5	-17	0	45	78.6%
5/6	NYK	L 121-117	36	6	2	8	0	4	3	5	2	40.0%	1	0	0.0%	6	2	33.3%	0	0	0.0%	0	2	2.7	-12	0	14	50.0%
5/2	MIL	W 120-98	31	17	6	10	0	0	2	10	2	20.0%	6	5	83.3%	16	7	43.8%	1	1	100.0%	1	5	5.0	+12	1	22	51.7%
4/30	MIL	L 115-92	33	16	4	6	0	0	2	10	4	40.0%	4	2	50.0%	14	6	42.9%	0	0	0.0%	1	3	3.0	-14	1	14	57.1%
4/28	MIL	W 126-113	32	24	4	4	0	1	3	12	5	41.7%	4	3	75.0%	16	8	50.0%	3	3	100.0%	0	4	1.3	+13	0	24	69.3%
4/26	MIL	W 121-118	45	18	10	16	1	0	4	12	1	8.3%	10	7	70.0%	22	8	36.4%	1	1	100.0%	5	5	4.0	+16	1	32	40.1%
4/23	MIL	W 125-108	36	12	4	12	1	1	2	7	3	42.9%	3	1	33.3%	10	4	40.0%	2	1	50.0%	1	3	6.0	+17	4	17	55.1%
4/21	MIL	L 109-94	37	9	7	8	1	1	3	3	1	33.3%	4	3	75.0%	7	4	57.1%	0	0	0.0%	1	6	2.7	-3	0	21	64.3%
Postseason Totals			34.8	18.7	4.8	8.2	0.7	1.3	2.1	9.3	3.5	37.9%	5.0	3.5	69.3%	14.3	7.0	48.8%	1.3	1.1	85.0%	0.8	4.0	4.0	+59	0.9	25.8	62.6%

Tyrese Haliburton

#0 PG

Status

Previous game (@ Celtics 5/23)

Latest Tyrese Haliburton news

Officially out

2023-24 Postseason Stats

2023-24 Season Stats

Tyrese Haliburton Career Stats

Career Averages

Career Averages

Tyrese Haliburton Season Stats 2023-24

Previous Game (@ Celtics 5/23)

2023-24 Stats

2023-24 Rebounding

2023-24 Defensive

2023-24 Shooting

2023-24 Advanced

2023-24 Stats

2023-24 Rebounding

2023-24 Defensive

2023-24 Shooting

2023-24 Advanced

Tyrese Haliburton Game Log 2023-24

Tyrese Haliburton Player Profile

Career History

Tyrese Haliburton Fantasy Projections

It's the offseason! 😎

Tyrese Haliburton Latest News

Officially out

Unlikely to play in Game 4

Questionable for Game 4

Set to miss game 3

Questionable for Game 3

Aggravates hamstring in Game 2

Done for night with leg issue

Double-doubles in Game 1 loss

Strong from deep in Game 7 win

Tyrese Haliburton

#0 PG

Status

Previous game (@ Celtics 5/23)

Latest Tyrese Haliburton news Subscribe

2023-24 Postseason Stats

2023-24 Season Stats

Latest Tyrese Haliburton news